Insmed’s Gene Therapy (INS1201) Poised to Challenge Duchenne Muscular Dystrophy (DMD) For its INS1201 Duchenne (DMD) gene therapy, Insmed intends to initiate Phase I clinical trials in the first part of the year 2025. Insmed is getting ready to use its ground-breaking gene therapy, INS1201, to combat Duchenne muscular dystrophy. Insmed intends to start Phase I clinical trials for INS1201 in the first half of 2025 after the FDA approved its investigational new drug (IND) application in December 2024. What is Insmed INS1201 Gene Therapy? Learn More: dmdwarrior.com

Insmed’s Gene Therapy (INS1201) Poised to Challenge Duchenne Muscular Dystrophy (DMD)

👉 Learn More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennewarriors #duchennesmusculardystrophy #duchenneheroes #musculardystrophy #gene #dna #insmed #ins1201